There has been a recent explosion of public interest in less invasive facial rejuvenation products and treatments. At the forefront of this are the U.S. FDA Approvals of Botox and Xeomin injections.

In addition to the broad array of cosmetic applications for botulinum toxin, a new range of functional treatments is similarly beginning to emerge. These treatments include creating a "chemical" tarsorrhaphy to promote corneal healing, reducing thyroid-associated eyelid retraction, and--most compelling--reducing the frequency and severity of muscle tension and migraine headaches. These...